Objectives To assess the accuracy of fetal RHD genotyping using cell-free fetal DNA in maternal plasma at different gestational ages.
Introduction
Haemolytic disease of the fetus and newborn is caused by maternal IgG antibodies to red cell surface antigens crossing the placenta and facilitating the immune destruction of fetal red cells or erythroid progenitors. The most commonly implicated antigen is the RhD (RH1) antigen of the rhesus system. Postnatal prophylaxis with anti-RhD immunoglobulin substantially reduces the alloimmunisation of RhD negative women and the prevalence of haemolytic disease of the fetus and newborn. 1 Subsequent introduction of routine antenatal prophylaxis with anti-RhD immunoglobulin in the third trimester for all RhD negative pregnant women is now standard in many countries. 2 In a predominantly white population, however, about 38% of these women would be carrying an RhD negative fetus and thus receive anti-RhD immunoglobulin, a pooled human plasma product, unnecessarily. 3 Prophylaxis after delivery is offered only to RhD negative women who have given birth to an RhD positive baby.
Since the identification of cell-free fetal DNA in the blood of pregnant women, 4 several laboratories have provided a fetal RHD genotyping service for RhD negative women with a measureable concentration of anti-RhD antibody. 5 Cell-free fetal DNA in maternal plasma is tested for the presence or absence of the RHD gene, and results are used to direct management of the pregnancy. 5 Consequent to the success of fetal RHD genotyping in high risk women, the National Institute for Health and Care Excellence has "endorsed studies into the feasibility of mass testing antenatally for fetal blood group by analysis of cell-free fetal DNA in maternal plasma." 2 If fetal RHD testing proved accurate enough, there would be no need to test cord red cells serologically for RhD status.
High risk alloimmunised women are tested with a labour intensive low throughput method, which is unsuitable for mass screening. 6 Two studies have used high throughput methods, including robotic isolation of plasma DNA and real time quantitative polymerase chain reaction (PCR) technology, to routinely determine fetal RHD status at 30 weeks in the Netherlands 7 and at 28 weeks in the United Kingdom, 8 with 99.4% and 95.7% diagnostic accuracy when compared with cord blood serology. If the results of the UK trials had been applied as a guide to treatment, only 2% of the women would have received anti-RhD immunoglobulin unnecessarily, compared with 38% in the absence of genotyping. Similar accuracy was achieved in validation studies in Germany 9 and France, 10 but the latter involved re-testing all negative results, which would be uneconomical. 10 In Denmark and the Netherlands routine fetal RHD genotyping has recently been introduced as a national service at 26 and 28 weeks, respectively. 11 12 As routine anti-RhD prophylaxis is recommended from 28 weeks, and anti-RhD immunoglobulin is administered earlier in pregnancy after any potential sensitising event, implementation of fetal RHD testing earlier in pregnancy would maximise potential benefits and cost reduction. As concentrations of cell-free fetal DNA in maternal blood increase throughout the pregnancy, 13 it cannot be assumed that tests will be as accurate early in pregnancy as they are at 26-28 weeks' gestation.
We estimated the diagnostic accuracy and costs of fetal RHD genotyping in RhD negative pregnant women from the time of booking until 28 weeks' gestation to determine the optimal gestation for implementation into routine clinical practice. The economic impact of testing will be reported separately.
Methods

Population
Women booking for antenatal care in 2009-12 at seven maternity units in England were prospectively asked for verbal consent to donate an additional 4 mL of blood at the time of their booking appointment. These appointments were in hospital antenatal clinics or the community according to local clinical practice. Local midwives got verbal consent from women when possible. Blood samples from RhD positive women were discarded, and those from RhD negative women were sent to the International Blood Group Reference Laboratory for fetal RHD genotyping, to arrive within 48 hours of blood being drawn. When possible, we also obtained consent to collect additional blood samples opportunistically for fetal RHD genotyping from RhD negative women with singleton pregnancies when they attended for Down's syndrome screening (at 11-20 weeks) and the routine anomaly scan (at 18-23 weeks) ( fig 1⇓) . While it is recommended that all women book for antenatal care early in pregnancy, before the offer of the combined screening test for Down's syndrome, which is performed at 11-13 weeks and 6 days, not all do. For the purpose of our study we included only women who booked before 24 weeks' gestation, agreed to participate in the study, and donated at least one blood sample before 24 weeks' gestation. Those who booked before 11 weeks might have donated up to four blood samples: at booking; at the time of screening for Down's syndrome (either the combined test at 11-13 weeks and 6 days or second trimester screening at 14-20 weeks); at the routine anomaly scan, which, although recommended at 18-21 weeks and 6 days, can be performed as late as 24 weeks in some circumstances; and after 25 weeks at the routine third trimester antenatal visit, when blood is taken to check haemoglobin and antibody concentrations.
Written informed consent was obtained before or at the routine third trimester visit (around 28 weeks), when the women were given the result of molecular testing and an additional blood sample was requested to confirm fetal RHD status. When third trimester testing confirmed that the fetus was RHD negative, women were allowed to opt out of receiving anti-RhD immunoglobulin if they requested to do so as the reliability of testing at this gestation is proved. 8 11 All women predicted to be carrying an RhD positive baby, or when the fetal genotyping result was inconclusive, were offered anti-RhD immunoglobulin according to local clinical practice. All women experiencing a sensitising event before 28 weeks' gestation were also offered anti-RhD immunoglobulin according to local clinical practice.
Fetal genotyping from maternal blood
On receipt of blood samples, plasma was prepared and analysed prospectively by using assay techniques and criteria for the determination of fetal RHD status as described previously. 
Serological RHD testing on cord bloods
RhD typing on cord blood samples was performed with serological methods routinely used by participating units. Results were ascertained by the research midwives and compared with the genotype predicted.
Data analysis
We included results obtained from RhD negative women before 25 weeks with a singleton pregnancy who gave written consent for fetal RHD genotyping and in whom a cord blood RhD group was subsequently obtained. Genotyping results were interpreted as RHD positive, RHD negative, or inconclusive. Sensitivity for the detection of RHD positivity was calculated on the basis that inconclusive results were treated as RHD positive. We used generalised linear models with random intercept to quantify trends in sensitivity and specificity with gestational age while taking into account repeat measures from the same woman. All estimates are presented with 95% confidence intervals. We used R (version 2.14.0) library glmmML to fit the models with 5000 bootstrap samples for estimation of standard errors.
Results
Women were recruited from 2009 to 2012. Of the samples received at the International Blood Group Reference Laboratory, 172 were excluded from the analysis because of extreme haemolysis (average transit time 8.5 days), and a further 22 were not analysed because they did not contain sufficient blood. Samples from 30 women were excluded because of multiple pregnancy, 185 because no cord blood result was subsequently obtained, and 372 because of lack of written consent. We included results of fetal RHD genotyping from 2288 women in the final analysis. We had 4913 fetal genotype results with up to four analyses per woman; 436 had only one measurement, 1132 had two, 667 had three, and 53 had four. Most women were white (78%), 5.8% were Asian, 3.9% were black or mixed race, and 12.3% were unknown. Gestational age at measurement varied from five to 35 weeks (mean 18.67, median 19). The odds of correctly identifying RHD positive and RHD negative fetuses increased significantly with gestational age, with low levels of false negative results after 11 weeks' gestation. Table 1 shows the summary statistics for <11, 11-13, 14-17, 18-23, and >23 weeks⇓. Figure 2⇓ shows how sensitivity for correctly identifying RHD positive fetuses increased on a week by week basis and how before 11 weeks, confidence intervals were wider and sensitivities not good enough to support routine introduction of the test.
Discussion
Previous studies have shown that mass throughput RHD genotyping of cell-free fetal DNA is accurate if performed in the third trimester of pregnancy. 7 8 In this population based cohort study, we evaluated accuracy across a wider range of gestations and have shown that it is highly accurate from 11 weeks' gestation; before this the percentage of babies falsely predicted as RhD negative increases. For routine application of fetal RHD genotyping, false negative results-whereby the fetus is predicted to be RhD negative when it is really RhD positive-pose the greatest concern as mothers will not receive prophylactic anti-RhD immunoglobulin and might alloimmunise, which would put babies in subsequent pregnancies at risk of considerable morbidity or mortality. As the sensitivity improves with gestation, this risk can therefore be mitigated by optimal timing of testing, by repeating cell-free fetal DNA testing in women predicted to be carrying an RhD negative baby, or by testing cord blood of babies predicted to be RhD negative. The latter two interventions would, however, impact on the cost effectiveness and applicability of a large scale programme. In our study, the incidence of false RHD negative results before 11 weeks' gestation was 16/865 (1.85%, 95% confidence interval 1.14% to 2.98%). This might be because of low concentrations of cell-free fetal DNA in early pregnancy. 13 After 11 weeks the incidence of false negative results was considerably lower (at 1/956 between 11-13 weeks; 0.1%, 0.02% to 0.59%) and did not decrease between 11 and 24 weeks, in line with recent evidence that concentrations of cell free fetal DNA increase only minimally between 10 and 20 weeks' gestation.
14 The small number of false RHD negative results after 11 weeks' gestation would only minimally increase the risk of alloimmunisation in the population, around 0.07/100 000 births (table 2⇓) . This figure could well be offset by the potential to improve overall uptake of the immunoprophylaxis programme for RhD negative women carrying an RHD positive baby, as counselling and follow-up could be targeted at these women to try to improve anti-RhD immunoglobulin uptake when it is definitively needed.
In Denmark 11 and the Netherlands 12 routine fetal RHD genotyping has been introduced at 25 and 28 weeks' gestation, respectively, and is used to direct routine third trimester antenatal prophylaxis with anti-RhD immunoglobulin. While such strategies can minimise the administration of unnecessary anti-RhD immunoglobulin in a routine immunoprophylaxis programme, they do not take account of anti-RhD immunoglobulin required for sensitising events earlier in pregnancy. Earlier knowledge of fetal RHD genotype would further reduce unnecessary administration of anti-RhD immunoglobulin as well as potentially enhancing any financial savings as prophylactic anti-RhD immunoglobulin and costly estimations of fetomaternal haemorrhage by Kleihauer-Betke test or flow cytometry could be avoided in RhD negative mothers carrying an RHD negative baby, savings realised not only for routine prophylaxis at 28 weeks but also for sensitising events occurring at earlier gestations. 15 
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Conclusions
Mass throughput fetal RHD genotyping is sufficiently accurate to be used from 11 weeks' gestation. To maximise reduction in administration of anti-RhD immunoglobulin and to minimise costs to both women and health services, testing should be performed as soon as possible from 11 weeks' gestation to coincide with routine antenatal visits.
What is already known on this topic
Previous studies have predominantly assessed accuracy of fetal RHD genotyping at relatively late gestations (24-30 weeks) At this stage in pregnancy it is highly accurate and can be used to direct immunoprophylaxis to those RhD negative women carrying an RHD positive baby and thereby reduce unnecessary exposure to anti-RhD immunoglobulin
What this study adds
Mass throughput fetal RHD genotyping is highly accurate from 11 weeks' gestation, but before this the number of babies falsely predicted to be RhD negative is high To maximise benefit of routine fetal RHD genotyping and to avoid potential sensitisation by withholding anti-RhD immunoglobulin in women falsely predicted to be carrying an RhD negative baby, testing should be done only from 11 weeks' gestation Tables   Table 1| Prediction 
